natgillin/translations-raw huggingface dataset:
The method according to claim 1, wherein said transporting includes transporting the composite material through the furnace in a manner such that the composite material is not rotated, tumbled, crushed, impacted, or passed around bends during transport through the furnace. 
Postupak prema bilo kojem od prethodnih patentnih zahtjeva naznačen time da transporter (6; 106) transportira miješani materijal (36) tako da se materijal ne rotira, prevrće, gužva ili stiska pri prolazu uz zavoje u prolazu kroz peć.
each U is independently a bond or an optionally substituted C1-C6alkylidene chain, wherein up to two methylene units of the chain are optionally and independently replaced by -NR'-, -CO-,-CONR'-, or -NR'CO; and each occurrence af R' is independently hydrogen or a C1-C6aliphatic group, 
je T-R', gdje T je veza ili je izborno supstituiran C1-C6alkilidenski lanac, gdje do dvije metilenske jedinice su izborno i neovisno zamijenjen s -O-, -S-, -NR'-, -OCO-, -COO-, -SO2- ili -CO-, a R' je vodik, C1-C4alkil, ili izborno supstituirana 5- ili 6-eročlana arilna ili heteroarilna skupina; ili
Use of (a) a corticosteroid as defined in any one of claims 1 and 3 to 7 for the preparation of a medicament, for simultaneous, concurrent, separate or sequential use in combination with (b) an antagonist of M3 muscarinic receptors as defined in claim 1 or 2 for the treatment of a respiratory disease as defined in claim 11 or 12. 
Uporaba (a) inhibitora PDE4 kako se definira u bilo kojem od patentnih zahtjeva 1 i 3 do 6, naznačena time, da se koristi za pripravu lijeka za istovremenu, paralelnu, odvojenu ili sekvencijsku primjenu u kombinaciji s (b) antagonistom muskarinskih receptora M3 kako se definira u patentnom zahtjevu 1 ili 2 za liječenje bolesti dišnih putova kako se definira u patentnom zahtjevu 10 ili 11.
and R3 are the same or different and each is a hydrogen atom, a halogen atom, an optionally substituted hydrocarbon group or an optionally substituted hydroxy group; 
i R3 su isti ili različiti i svaki je atom vodika, atom halogena, opcijski supstituirana ugljikovodična skupina ili opcijski supstituirana hidroksi-skupina;
Lid according to one of claims 15 or 16, characterized in that the first plastic material is General Purpose Polystyrene (GPPS). Lid according to one of claims 15 to 17, characterized in that the second plastic material is High Impact Polystyrene (HIPS). 
Poklopac prema jednom od prethodnih patentnih zahtjeva, naznačen time da su oba navedena, prvi kao i drugi, plastična materijala polistireni, i time daje prvi plastični materijal polistirEn opće namjene (GPPS) i time da je drugi materijal polistiren visokog djelovanja (HIPS).
20 A composition suitable for control of diseases caused by phytopathogens comprising a synergistically effective amount of (A) a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and 
Pripravak koji je pogodan za nadzor bolesti uzrokovanih fitopatogenim organizmima uključujući (A) spoj formule I UA naznačen time da je R, difluorometil ili trifluorometil, a X kloro, fluoro, ili bromo; i (B) spoj biksafen.
Advantageously, the aerosol generating means includes a heat stable substrate including one or more aerosol forming substances. Preferably, the heat exchange relationship between the fuel and the aerosol generator is achieved by providing a heat conducting member, such as a metal foil, which efficiently conducts or transfers heat from the burning fuel element to the aerosol generating means. 
Pogodno, sredstvo za generiranje aerosola uključuje jednu ili više supstanci za formiranje aerosola, Poželjno, odnos za toplinsku razmjenu između goriva i generatora aerosola postiže se osiguravanjem člana koji provodi toplinu, kao što je metalna folija, koja efikasno provodi ili prenosi toplinu sa izgorivog gorivog elementa na sredstvo za generiranje aerosola.
Genetically altered obese diabetic mice (db/db) (male, 7-9 weeks old) are housed (7-9 mice/cage) under standard laboratory conditions at 22°C and 50% relative humidity, and maintained on a diet of Purina rodent chow and water ad libitum. 
Genetički promijenjeni debeli dijabetički miševi (db/db) (muški, 7-9 tjedana stari) su smješteni (7-9 miševa/kavez) uz standardne labaratorijske uvjete pri 22*C i 50% relativne vlage, te su držani na dijeti Purina hrane i vode ad libitum.
The apparatus according to Claim 1, wherein the lower threshold value of the absorbed current is the minimum value (IMIN) of current delivered by the plant- controller electronic card, such as to guarantee the minimum current on the axle of the train sufficient for detection of the codes on board the train in the worst conditions, namely maximum length and maximum dispersions. 
Uređaj u skladu s patentnim zahtjevom 1, naznačen time što je iznos nižeg praga apsorbirane struje minimalni iznos (IMIN) struje isporučene od elektroničke kartice za upravljanje uređajem, tako da se garantira minimalna struja na osovini vlaka koja je dovoljna za detektiranje kodova na komandnoj ploči vlaka u najgorim uvjetima, naime za maksimalnu duljinu i za maksimalno rasipanje.
The method of claim 14, wherein the thermoset polyurethane comprises a polymer chain and cross-linking members, said thermoset polyurethane further including unsaturated bonds in the polymer chains and crosslinkers, initiators, or both as cross-linking members. 
Uređaj za oslobađanje lijeka prema patentnom zahtjevu 16, naznačen time što termoreaktivni poliuretan sadrži polimerni lanac i unakrsno vezane članove, termoreaktivni poliuretan dalje sadrži nezasićene veze u polimernim lancima i odgovarajuće unakrsno vezana sredstva i/ili inicijatore kao unakrsno vezane članove.
In yet other embodiments of the reagent, the kosmotrope is selected from the group consisting of Glycerol, Trimethylamine N-oxide, Ectoine, a,a-Trehalose, 3-Dimethylsulfoniopropionate, Glucose, Dextran, or D-Lactose. 
Reagens prema zahtjevu 1, naznačen time da je daljnji kozmotrop odabran iz skupine koja sadrži glicerol, trimetilamin N-oksid, ektoin, 3-dimetilsulfoniopropionat, glukozu, dekstran, i D-laktozu.
The latter type of oligofructose, also called fructo-oligosaccharide, always has a terminal glucose residue, since it is derived from sucrose. 
Ovaj potonji tip oligofruktoze naziva se frukto-oligosaharidom 1 uvijek sadržava terminalnu glukoznu jedinicu jer je izveden iz saharoze.
Reference 58 discloses mutation of a native Xaa1-Asp-Xaa2 tripeptide sequence, where Xaa1 is Leu, Ile, Gly or Val, and Xaa2 is Val, Leu or Ser, in order to reduce vascular leak. 
Referenca 58 otkriva mutaciju nativne Xaa-Asp-Xaa" tripeptidne sekvence, gdje Xaa' je Leu, Ile, Gly ili Val, a Xaa" je Val, Leu ili HR P20070487 T3 Ser, da bi se smanjio izljev iz krvne žile.
The domain antibody (dAb) according to any one of claims 1-12 for the use according to claim 14, wherein the patient has or is at risk of having an autoimmune disease or a graft-related disease, preferably a disease selected from the group consisting of an allograft rejection, a xenograft transplant rejection, graft versus host disease, systemic lupus erythematosis, multiple sclerosis, rheumatoid arthritis, diabetes, psoriasis, scleroderma, atherosclerosis, inflammatory bowel disease, and ulcertative colitis. 
Antitijelo koje sadrži jednu imunoglobulinsku varijabilnu domenu ili dvojno specifični ligand za uporabu prema zahtjevu 11, naznačeni time, što se spomenuta bolest u svezi sa kalemom bira iz grupe koja se sastoji od odbacivanja alokalmea, odbacivanja ksenokalemskog transplanta 1 bolesti kalema protiv domaćina; ili gdje se spomenuta autoimunska bolest bira iz grupe koja se sastoji od sustavnog eritemskog lupusa, multiple skleroze, reumatoidnog artritisa, dijabetesa, psorijaze, skleroderme, Sjčgren-ovog sindroma, ateroskleroze, upalne bolesti crijeva, Crohn-ove bolesti i ulcerativnog kolitisa.
The compounds of the present invention may be employed in combination with a PPAR Y agonist such as a thiazolidinedione oral anti-diabetic agent or other insulin sensitizers (which has an insulin sensitivity effect in NIDDM patients) such as rosiglitazone (SKB), pioglitazone (Takeda), Mitsubishi's MCC-555 (disclosed in U.S. Patent No. 
Spojevi prikazanog izuma mogu se koristiti u kombinaciji sa PPAR y agonistima kao što su tiazolidindion oralno protudijabetesno sredstvo ili druga osjetna sredstva za inzulin (koja imaju efekt osjeta na inzulin kod NIDDM pacijenata) kao što je rosiglitazon (SKB), pioglitazon (Takeda), Mitsubishijev MCC-555 (prikazan u U.S. Patentnom br.
The electric motor 12 is connected to a gear box 13 fixed to a motor block support 16. 
Elektromotor 12 je spojen na zupčani prijenosnik 13 koji je pričvršćen na nosač bloka motora 16.
the housing has on the upper end wall a mounting opening for access to the lever mechanism. 
kućište (20) ima na gornjoj strani otvor za montažu (56) za pristup mehanizmu poluge (5.1, 5.2).
continuing to receive the MBMS service and refraining from receiving the unicast service when the user indicates a desire to continue receiving the MBMS service. The method of claim 1, further comprising: 
prestanka primitka MBMS servisa i primitka unicast servisa kada korisnik iskaže želju da primi unicast servis; i nastavka sa primitkom MBMS servisa i suzdržavanja od primitka unicast servisa kada korisnik iskaže želju da nastavi sa primitkom MBMS servisa.
The topical composition according to claim 6, wherein the pharmaceutically acceptable carrier is selected from the group consisting of sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions. 
Topička kompozicija za uporabu prema patentnom zahtjevu 3, naznačeno time da je farmaceutski prihvatljiv nosač izabran iz grupe koja se sastoji od sprejeva, maglica, aerosola, otopina, losiona, gelova, krema, masti, pasta, melema, emulzija i suspenzija.
f') choosing internal reference autosomes IRA from candidate internal reference autosomes on the basis of the coefficient of variation CV thereof, while potentially aneuploid chromosomes are excluded; 
1) odabir internih referentnih autozoma IRA iz kandidata internih referentnih autozoma na osnovi njihovog koeficijenta varijacije (CV), pri čemu su isključeni potencijalno aneuploidni kromosomi;
Container (1) according to claim 6, wherein the constriction abuts or near abuts the bottom of the casing (2). 
Spremnik (1) u skladu s patentnim zahtjevom 6, naznačen time što suženje dodiruje ili gotovo dodiruje dno tijela
The in vitro diagnostic method of any one of items 1 to 37, 45 to 53 and 58 to 73 comprising providing a uterine fluid sample obtained from a patient with a pipelle device or syringe wherein the patient has a risk factor or symptom of endometrial cancer; contacting said sample with an agent capable of preserving, preventing, or lessening the degradation of RNA in said uterine fluid sample; determining in said sample the expression level of mRNA corresponding to said from 1 to 20 markers and one or more endogenous genes using quantitative PCR; normalizing the expression level of said from 1 to 20 biomarkers with the one or more endogenous genes; comparing the normalized level of the from 1 to 20 biomarkers to a control value wherein differential expression of from1 to 20 of the biomarkers indicates endometrial cancer or an increased likelihood of endometrial cancer. 
Postupak dijagnosticiranja in vitro u skladu s bilo kojim od patentnih zahtjeva 1 do 15 i 17 do 20, naznačen time što se sastoji u osiguravanju uzoraka maternične tekućine uzetog iz pacijentice uz pomoć pipele ili injekcijske šprice, gdje pacijentica posjeduje čimbenik rizika ili pokazuje simptom raka endometrija; miješanju navedenog uzorka sa sredstvom koje može konzervirati, spriječiti ili smanjiti razgradnju RNA u navedenom uzorku maternične tekućine; određivanju u navedenom uzorku razine eksprimiranja mRNA koja odgovara navedenom biomarkeru P4HB i, izborno, jednom biomarkeru koji se bira između ACAAI1, APIM2, CGN, DDR1, EPS8L2, FASTKDI, GMIP, IKBKE, P2RX4, PHKG2, PPFIBP2, PPPIRI6A, RASSF7, RNF183, SIRT6, TIP3, EFEMP2, SOCS2 i DCN, i jednog ili više endogenih gena uz pomoć kvantitativnog PCR;
subjects having a serum LDL-C level of at least 100 mg/dL [at least 130 mg/dL/at least 160 mg/dL/at least 200 mg/dL]; subjects having a serum HDL-C level of less than 40 mg/dL; 
(1) - subjekti s razinom LDL-kolesterola u serumu (LDL-C) od barem 100 mg/dL., (1) subjekti koji imaju razinu HDL-C u serumu manju od 40 mg/dI;
A compound according to claim 32 wherein R1 is phenylmethyl, pyridinylmethyl, or furanylmethyl; wherein phenyl, pyridinyl, and furanyl are optionally substituted with one to three R11 substituents independently selected from is the group consisting of methoxy, tetrazolyl, cyclopropylaminocarbonyl, (2-hydroxyeth-1-yl)aminocarbonyl, phenylaminocarbonyl wherein phenyl is optionally substituted with carboxy, morpholin-4-ylcarbonyl, methoxycarbonyl, and carboxy; provided that no more than one R11 is phenylaminocarbonyl. 
33. Spoj prema zahtjevu 32 naznačen time da R' je fenilmetil, piridinilmetil ili furanilmetil; pri čemu fenil, piridinil i furanil su proizvoljno supstituirani sa jednim do tri R'! supstituenta nezavisno izabrana iz skupine koju čine metoksi, tetrazolil, ciklopropilaminokarbonil, (2-hidroksiet-1-il)aminokarbonil, fenilaminokarbonil pri čemu fenil jo proizvoljno supstituiran sa karboksi, morfolin-4-ilkarbonil, metoksikarbonil i karboksi; uz uvjet da ne više od jedan R'' je fenilaminokarbonil.
from 0 to 40 % other active ingredients by weight; wherein the sum of the components is 100%. 
(e) od 0 do 40 % težinski kiseline; te (D od 0 do 40 % težinski drugih aktivnih sastojaka; pri čemu je zbroj komponenata 100%.
A safety glove (2) according to claim 6 or 7, wherein said attachment (1) is made of metal. 
Zaštitna rukavica (2) u skladu s patentnim zahtjevom 6 ili 7, naznačena time što je navedeni dodatak (1) načinjen od metala.
An (aza)indole derivative as claimed in claim 4, wherein the group represented by the general formula: is a group represented by the following general formula (IIa): in the formula, Z1, Z2 and Z3 independently represent CR7 or N; and Y1 and R7 independently represent a hydrogen atom, hydroxy, amino, a halogen atom, lower alkyl or lower alkoxy with the proviso that when two or more R7 exist, these R7 are optionally the same or different from each other, or a prodrug thereof, or a pharmaceutically acceptable salt thereof. 
, Z2 i Z3 nezavisno predstavljaju CR7; i predstavlja hidroksi, amino, atom halogena, niži alkil ili niži alkoksi; i predstavlja atom vodika, hidroksi, amino, atom halogena, niži alkil ili niži alkoksi uz uvjet da kada dva ili više R7 postoje, ti R7 su po izboru isti ili međusobno različiti, ili njegov prolijek, ili farmaceutski prihvatljiva sol, ili gdje
One particular aspect of the present invention includes an apparatus, method, and system for applying a biologically active or chemical substance to a relatively large volume of target product, including crop. 
U drugom aspektu izuma osiguran je postupak za nanošenje relativno malog volumena biološki aktivne ili kemijske supstance na relativno veliki volumen poljoprivrednih usjeva, a koji se sastoji od:
The bag-in-container according to claim 1, wherein the inner and outer layer are a material selected from PET, PEN, PTT, PA, PP, PE, HDPE, EVOH, PGAc, PLA, and copolymers or blends thereof. 
(21) i vanjski (22) sloj od materijala izabranih od PET, PEN, PTT, PA, PP, PE, HDPE, EVOM, PGAc, PLA i kopolimera ili njihovih mješavina.
The characteristics of these engraving were as follows: 
Obilježja navedenih gravura su sljedeća:
A multi-room building, comprising a corridor extending horizontally, and at least a first part of a building according to clause 17 arranged on a first side of said corridor, and a second part of a building according to clause 17 arranged on the opposite side of said corridor, wherein said second part of the building is aligned with the first part of the building. A building constructed in accordance with a method as defined in any one of clauses 1-16, respectively. 
Postupak sukladno zahtjevu 17 ili 18, nadalje sadrži korak proširenja navedene višesobne građevine u horizontalnom smjeru na način da svaki dio građevine, omogućen sukladno postupku iz bilo kojeg od zahtjeva 1 do 16, s prve strane hodnika je poravnat s odgovarajućim dijelom građevine na suprotnoj strani hodnika.
The use according to claim 1, wherein said adhesive compositions are those obtained from wet compositions selected from the group consisting of: acrylic resin-based solutions in an organic solvent, acrylic resin/natural or synthetic rubber-based solutions in an organic solvent, 
Uporaba u skladu s patentnim zahtjevom 1, pri čemu su navedeni adhezivni sastavi oni dobiveni iz mokrih sastava odabranih iz grupe koja se sastoji od: a) otopina na bazi akrilne smole u organskom otapalu, b) otopina na bazi akrilne smole/prirodne ili sintetske gume u organskom otapalu,
The method of clause 12, wherein the daily dose is about 5 mg/day. 
Spoj za uporabu sukladno patentnom zahtjevu 9, naznačeno time da je dnevna doza oko 5 mg/dan.
1 having a dynamic vapor sorption profile substantially as shown in Figure 12 . 
Hemihidrat u skladu sa zahtjevom 1, naznačen time, da ima profil dinamičke sorpcije para sadržajno isti kao prikazan na Slici 12.
mg of said oxycodone or pharmaceutically acceptable salt thereof, and at least 54% by weight of said high molecular weight polyethylene oxide; and 
najmanje jedan polietilen oksid koji ima, prema reološkim mjerenjima, približnu molekularnu težinu od najmanje 1,000,000; te
A hemihydrate according to claim 1 having an X-ray powder diffraction pattern comprising peaks, in terms of 2θ, at about 13.7°, about 14.9°, about 15.4°, about 15.8°, about 16.7°, about 20.1°, and about 21.4°. 
Hemihidrat u skladu sa zahtjevom 1, naznačen time, da ima uzorak difrakcije praha X-zrakama koji sadrži pikove, u značenju 20, na oko 13.7%, oko14.9%, oko 15.4%, oko 15.8%, oko 16.7, oko 20.1% i oko 21.4".
X, Z and M all represent direct bonds, R3 represents hydrogen, then R2 does not represent 1-piperidinyl when R1 represents unsubstituted phenyl. 
X, Z i M svi predstavljaju izravne veze, R3 predstavlja vodik, tada R2 ne predstavlja 1-piperidinil kada R1 predstavlja nesupstituirani fenil.
said first DNA molecule comprises at least 18 contiguous nucleotides complementary to the heterologous insert DNA portion of SEQ ID NO:5, and wherein said second DNA molecule comprises at least 18 contiguous nucleotides from the corn genome portion of SEQ ID NO:3; or 
(i) se prva navedena DNA molekula sastoji od najmanje 18 u nizu poredanih nukleotida komplementarnih sa heterolognim dijelom unutar DNA SEQ ID NO: 5, i pri čemu se navedena druga DNA molekula sastoji od najmanje 18 u nizu poredanih nukleotida iz dijela SEQ ID NO: 3 kukuruznog genoma; ili
The water-based herbicidal suspension according to Claim 3, wherein the inorganic salt is at least one member selected from the group consisting of sodium dihydrogenphosphate and potassium dihydrogenphosphate. 
Herbicidna suspenzija na bazi vode u skladu s patentnim zahtjevom 3, naznačena time, da je anorganska sol barem jedan od članova odabranih iz skupine koja se sastoji od natrijeva dihidrogenfosfata i kalij dihidrogenfosfata.
The circuit of claim 1, comprising a first module for determining a frequency offset of an analog communication signal and a second module for determining a frequency offset of a digital communication signal, these modules being adapted to receive a corresponding demodulated communication signal at their inputs. 
Raspored prema zahtjevima 2 i 3, naznačen time, da sadrži prvi modul (30) za određivanje odlazne frekvencije analognog komunikacijskog signala i drugi modul (32) za određivanje odlazne frekvencije digitalnog komunikacijskog signala, pri čemu su ti moduli podešeni za primanje odgovarajućih demoduliranih komunikacijskih signala na njihovim ulazima.
It should be noted, that there is no unambiguous clinical evidence for the analgesic effect of the tolperisone. 
Treba napomenuti da nema nedvojbenih kliničkih dokaza za analgetički učinak tolperisona.
In some embodiments, during the course of the reaction an amount in the range from about 30 to about 20000 ppm by weight, for example about 1000 to about 20000 ppm, of ferric chloride is maintained in the reaction zone. A process for the preparation of 1,1,2,3-tetrachloropropene may use reactive distillation. In general such a process includes dehydrochlorinating 1,1,1,2,3-pentachloropropane in a reaction zone in the presence of ferric chloride to produce 1,1,2,3-tetrachloropropene and hydrogen chloride, wherein the 1,1,2,3-tetrachloropropene and the hydrogen chloride are removed from the reaction zone by distillation during the course of the dehydrochlorination reaction, for example being removed as they form, continuously or substantially continuously. 
HR P20140465 T1 PATENTNI ZAHTJEVI Postupak proizvodnje 1,1,2,3-tetrakloropropena, postupak obuhvaća: pripremu 1,1,1,2,3-pentakloropropana zagrijavanjem reakcijske smjese koja sadrži 1,1,1,3-tetrakloropropan, željezov(III) klorid i klor radi dobivanja 1,1,1,2,3-pentakloropropana, gdje reakcijska smjesa po izboru dalje sadrži ugljik tetraklorid količini do 50% težine reakcijske smjese; i dehidrokloriranje 1,1,1,2,3-pentakloropropana u reakcijskoj zoni za dehidrokloriranje u prisutnosti željezovog(IID) klorida radi dobivanja 1,1,2,3-tetrakloropropena i klorovodika, gdje se 1,1,2,3-tetrakloropropen i klorovodik uklanjanju iz reakcijske zone za dehidrokloriranje putem destilacije tijekom reakcije dehidrokloriranja.
The invert arm assembly of claim 17 which also includes a second idler gear (136b) connected to the other idler gear by a suspension mechanism that permits relative movement of the idler gears (136a, 136b) while maintaining meshed engagement of both idler gears with the drive gear and the driven gear. 
Sklop invertirajuće ruke iz zahtjeva 17 naznačen time da uključuje i drugi potporni zupčanik (136b) spojen na prvi potporni zupčanik preko amortizacijskog mehanizma koji dopušta relativno pomicanje potpornih zupčanika (136a, 136b), dok istovremeno zadržava kontakt oba potporna zupčanika s pogonskim i pogonjenim zupčanikom.
In a second method, sugar or sugar replacer are dissolving in 40 % fat cream prior to mixing. 
U drugoj su metodi šećer ili zamjena za šećer rastopljeni u slatkom vrhnju s 40 % mliječne masti prije miješanja električnom miješalicom.
The pharmaceutical package of item 174, wherein the antibody wherein said whole antibody or antibody fragment is a human, humanized, chimerized or deimmunized antibody or antibody fragment. 
Uporaba prema zahtjevu 34, naznačena time, što je spomenuto cijelo antitijelo ili dio antitijela humano, humanizirano, himerizirano ili deimunizirano antitijelo ili dio antitijela.
The process according to claim 1, which process additionally comprises a step (III) of contacting the pressed and heated product with a reagent which functionalises the product of step (II) as a chromatography medium. 
kontakta prešanog i zagrijanog proizvoda s reagensom koji funkcionalizira proizvod iz koraka (II) u sredstvo za kromatografiju.
The method according to item 2, wherein the method further comprises the step of applying moisture on the powder based sub layer (12) and thereafter applying heat in order to dry the powder based sub layer (12). 
Metoda u skladu sa patentnim zahtjevom 2, gdje metoda dalje sadrži korak nanošenja vlage na pod-sloj sa osnovom od praha (12) i zatim primjenu topline sa ciljem da se osuši pod sloj sa osnovom od praha (12).
The invention relates to an electrically conductive floor covering. 
Izum se odnosi na podnu oblogu koja provodi električnu struju.
The compound for use according to any preceding claim, further comprising administration of an additional anti-viral agent. The compound for use according to claim 9, wherein the additional anti-viral agent is selected from the group consisting of laninamivir, oseltamivir, zanamivir, and peramivir. 
Spoj za uporabu sukladno bilo kojem od predhodnih zahtjeva, koje nadalje sadrži davanje dodatnog antivirusnog sredstva, pri čemu je opcijski dodatno antivirusno sredstvo laninamivir, oseltamivir, zanamivir, ili peramivir.